Chief Executive Mike Doustdar’s comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
321last 24h
2134last 7d
379● bullish (7d)
186● bearish (7d)
204publishers
The Wall Street Journal7d agoneutral
Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative DealsInvestor's Business Daily36d agoneutral
Eli Lilly's Market Cap Balloons Again On This IPO's SetbackEli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.
Investor's Business Daily92d agoneutral
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In ObesityAnalysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.